Introduction of tyrosine kinase inhibitors (TKI) dramatically improves the treatment and
survival of the patients with chronic myeloid leukemia (CML) in the last decade. Imatinib (IM) …

Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …

Objective: The prognosis for chronic myeloid leukemia (CML) has been significantly
improved in the era of tyrosine kinase inhibitors (TKIs) whose leader is Imatinib mesylate …

Background Imatinib mesylate has revolutionized the treatment of patients with chronic
myeloid leukaemia (CML); however, some patients fail to respond and have a poor …

Introduction: Tyrosine kinase inhibitors (TKIs) have dramatically changed the outcome of
chronic myeloid leukemia (CML) patients. Recent research focused on TKI discontinuation …

Chronic myeloid leukemia (CML) respond dramatically to molecular target therapy; imatinib
(IM), a first generation tyrosine kinase inhibitor (TKIs). Quantitation of cytokines like …

Recent long term clinical outcome data have now established 400 mg/d of imatinib as the
first line treatment for newly diagnosed patients with CML. We report here the kinetics of …

The objective of this paper is to examine the effects of Imatinib on patients who are at the
chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML …

The introduction of imatinib has significantly changed prognosis of CML patients. Despite
favourable hematologic and cytogenetic response (CyR) data, patients (pts) on first line …

Aim: The aim of this study was to evaluate the response and resistance of cases to chronic
myeloid leukemia (CML) therapy with tyrosine kinase (TK) inhibitors (imatinib mesylate) and …